Esperion Launches New Scientific Website

Go back to Esperion Launches New Scientific Website

Morgan Stanley Opens Catalyst Driven Idea on Esperion Therapeutics (ESPR)

February 27, 2023 4:21 PM UTC

Morgan Stanley analyst Jeffrey Hung reiterated an Equalweight rating and $9.00 price target on Esperion Therapeutics (NASDAQ: ESPR)

The analyst comments "What is the catalyst? Data from Esperion's CLEAR outcomes study for LDLlowering drug Nexletol (bempedoic acid) in 14,000+ statin intolerant patients at high risk for cardiovascular disease will be presented in a... More